Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmaNetics' heparin assay trial completed:

This article was originally published in Clinica

Executive Summary

PharmaNetics Inc has completed a Phase I field trial of its rapid in vitro assay for monitoring the anticoagulant effects of enoxaparin, Aventis Pharmaceutical's low molecular weight heparin product marketed in the US as Lovenox and elsewhere as Clexane. According to PharmaNetics, the results of the trial show a sufficient correlation with standard laboratory methods to justify proceeding with trials needed for FDA submission. PharmaNetics has optimised the assay's test card formulation and is now validating its manufacturing process.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT076875

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel